Tandem Diabetes Care Appoints Sandra Beaver to Board of Directors

• Tandem Diabetes Care, Inc. announced that it had appointed Sandra Beaver to its board of director
• She has been appointed to the board as an independent director

Tandem Diabetes Care, Inc. a diabetes-focused technology company that develops products to deliver insulin to diabetics, today announced the appointment of Sandra Beaver to the Board of Directors, effective November 7, 2025.

Sandra will be serving as an independent director on the Board and as a member of the Audit Committee and Cybersecurity and Data Oversight Committee.

"The Board is extremely pleased to welcome Sandra to the Boards of Directors," said John Sheridan, Tandem Diabetes Care's President and CEO.

"Her extensive financial background and perspective will be helpful in supporting Tandem's expansion into the full potential of our digital health solutions and growing into new markets."

"I am excited to join the Board of Directors and I see all kinds of upside potential for Tandem to continue innovating and growing sustainably while making a difference for the community with diabetes and to our shareholders," said Sandra.

Sandra has more than 20 years of strategic and operational finance experience with worldwide exposure across healthcare, medical devices, gaming, technology, and manufacturing.

Currently, she is the Chief Financial Officer at Lyra Health, where she leads all finance and accounting, investor relations, facilities, procurement, and corporate development responsibilities.

Before joining Lyra Health, she served as the Chief Financial Officer for Evolus, a publicly traded medical aesthetics company, and held senior finance roles at Experian and IGT.

Sandra has a Bachelor of Business Administration Degree from the University of Massachusetts and a Professional Designation in Relational Database Design from UCLA.